GO:2000509 negative regulation of dendritic cell chemotaxis: Immune Regulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000509 describes any process that stops, prevents, or reduces the frequency, rate, or extent of dendritic cell chemotaxis.
• Dendritic cell chemotaxis is essential for bridging innate and adaptive immunity by guiding antigen-bearing dendritic cells to lymph nodes.
• Negative regulation of this process can be mediated by soluble factors such as IFN-gamma and IFN-beta, which suppress CCR7 expression and migratory capacity.
• Nuclear receptors like liver X receptors (LXRs) transcriptionally regulate dendritic cell chemotaxis, providing a layer of negative control.
• Viral pathogens such as human cytomegalovirus can modulate this pathway by degrading CYTIP, thereby altering dendritic cell adhesion and migration.
• Dysregulation of dendritic cell chemotaxis is implicated in chronic inflammation, autoimmunity, and impaired anti-tumor immunity.
Description
Dendritic cells (DCs) are professional antigen-presenting cells that patrol peripheral tissues and migrate to secondary lymphoid organs to initiate T cell responses. This migration is directed by chemokines and their receptors, a process known as dendritic cell chemotaxis. The frequency, rate, and extent of this migration must be tightly controlled to avoid excessive or misplaced immune activation. GO:2000509, negative regulation of dendritic cell chemotaxis, captures the biological processes that restrain this migration. Understanding this term is critical for immunologists studying infection, autoimmunity, and cancer, as manipulating DC migration can enhance or dampen immune responses. Experimental evidence shows that cytokines such as IFN-gamma and IFN-beta can negatively regulate DC migration by suppressing CCR7 and matrix metalloproteinase 9 (MMP-9). Additionally, nuclear receptors like LXRs act as transcriptional regulators of DC chemotaxis, highlighting the diversity of negative regulatory mechanisms. This article synthesizes current knowledge on GO:2000509, covering its definition, key genes, disease relevance, and research methodologies.
negative regulation of dendritic cell chemotaxis At A Glance
| GO ID | GO:2000509 |
|---|---|
| GO term | negative regulation of dendritic cell chemotaxis |
| Ontology | biological_process |
| Synonym | None |
| Major function | Suppression of directed dendritic cell migration in response to chemokine gradients |
| Regulatory factors | IFN-gamma, IFN-beta, liver X receptors (LXRs), CYTIP |
| Associated diseases | Chronic inflammation, autoimmunity, viral infections, cancer |
| Research methods | Transwell migration assays, live imaging, transcriptomics, CRISPR screens |
What Is GO:2000509?
According to the Gene Ontology, GO:2000509 (negative regulation of dendritic cell chemotaxis) is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of dendritic cell chemotaxis. In simpler terms, it encompasses all molecular and cellular events that put the brakes on the directed movement of dendritic cells toward chemical cues, such as chemokines. This regulation ensures that dendritic cells do not migrate excessively or to inappropriate locations, which is vital for maintaining immune homeostasis.
Why Is negative regulation of dendritic cell chemotaxis Important in Cell Biology?
Negative regulation of dendritic cell chemotaxis is crucial for preventing aberrant immune responses. Without proper control, dendritic cells may over-migrate to lymph nodes or peripheral tissues, leading to chronic inflammation, autoimmunity, or impaired pathogen clearance. This process also influences the efficacy of cancer immunotherapy, as tumor-induced suppression of DC migration can limit T cell priming. Therefore, understanding the molecular players that negatively regulate DC chemotaxis offers therapeutic opportunities to modulate immune responses in disease settings.
• Prevents excessive dendritic cell accumulation in lymph nodes, avoiding autoimmunity.
• Limits immunopathology during viral infections by controlling DC trafficking.
• Modulates anti-tumor immunity; negative regulators can be targeted to enhance DC migration to tumors.
• Influences vaccine efficacy by affecting DC migration to draining lymph nodes.
• Provides a mechanism for pathogens like HCMV to evade immune surveillance by altering DC migration.
• Nuclear receptors such as LXRs link lipid metabolism to DC chemotaxis regulation.
• Dysregulation is associated with chronic inflammatory diseases like asthma.
• Offers targets for therapeutic intervention in autoimmune diseases and cancer.
• Helps maintain immune tolerance by preventing inappropriate DC activation and migration.
• Key for understanding how cytokines shape adaptive immunity through DC trafficking.
What Happens During negative regulation of dendritic cell chemotaxis?
Initiation by Cytokine Signals
In simple terms: Certain immune signals tell dendritic cells to stop moving.
Negative regulation of dendritic cell chemotaxis often begins with extracellular cues such as IFN-gamma or IFN-beta. IFN-gamma has been shown to negatively regulate dendritic cell migration and T cell priming, acting as a brake on DC trafficking. Similarly, IFN-beta inhibits DC migration through STAT-1-mediated transcriptional suppression of CCR7 and MMP-9. These cytokines bind to their receptors on DCs, triggering intracellular signaling cascades that ultimately reduce the cell's migratory capacity.
Transcriptional Suppression of Chemokine Receptors
In simple terms: The cell reduces the production of receptors that sense chemokines.
A key step in negative regulation is the downregulation of chemokine receptors, particularly CCR7, which directs DCs to lymph node chemokines CCL19 and CCL21. IFN-beta suppresses CCR7 transcription via STAT-1, thereby reducing the cell's ability to respond to chemotactic gradients. Similarly, liver X receptor (LXR) activation transcriptionally regulates DC chemotaxis, likely by modulating chemokine receptor expression. This transcriptional control ensures that DCs become less responsive to migratory cues.
Inhibition of Matrix Metalloproteinases
In simple terms: Enzymes that help cells move through tissues are blocked.
Matrix metalloproteinase 9 (MMP-9) is required for dendritic cells to degrade extracellular matrix and migrate through tissues. IFN-beta inhibits DC migration partly by suppressing MMP-9 expression through STAT-1. This reduces the ability of DCs to penetrate basement membranes and reach lymph nodes. Thus, negative regulation of chemotaxis also involves remodeling the extracellular environment to impede movement.
Modulation of Adhesion Molecules
In simple terms: The cell's ability to stick to surfaces is altered to reduce movement.
Dendritic cell migration requires dynamic adhesion to endothelial and extracellular matrix components. Human cytomegalovirus (HCMV) induces degradation of CYTIP, a protein that regulates integrin-mediated adhesion, thereby modulating DC adhesion and migration. This viral strategy highlights how negative regulation can occur at the level of adhesion molecules, affecting the cell's ability to physically move.
Integration of Metabolic and Nuclear Receptor Signaling
In simple terms: Metabolic sensors can also put the brakes on dendritic cell movement.
Liver X receptors (LXRs), which are activated by oxysterols, act as transcriptional regulators of dendritic cell chemotaxis. LXR activation can suppress DC migration, linking lipid metabolism to immune cell trafficking. This represents a layer of negative regulation that integrates environmental metabolic cues with migratory decisions, ensuring DCs respond appropriately to systemic signals.
Key Genes Involved in GO:2000509 negative regulation of dendritic cell chemotaxis
The following genes and proteins have been experimentally implicated in the negative regulation of dendritic cell chemotaxis, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNG | Cytokine that negatively regulates DC migration and T cell priming | Studied in infection and autoimmunity models |
| IFNB1 | Cytokine that inhibits DC migration via STAT-1-mediated suppression of CCR7 and MMP-9 | Therapeutic potential in autoimmune diseases |
| STAT1 | Transcription factor mediating IFN-beta effects on DC migration | Key signaling node in negative regulation |
| CCR7 | Chemokine receptor whose downregulation reduces DC migration to lymph nodes | Target for modulating immune responses |
| MMP9 | Matrix metalloproteinase required for DC migration; suppressed by IFN-beta | Biomarker and therapeutic target |
| NR1H2 | Liver X receptor beta; transcriptionally regulates DC chemotaxis | Metabolic-immune crosstalk |
| NR1H3 | Liver X receptor alpha; transcriptionally regulates DC chemotaxis | Metabolic-immune crosstalk |
| CYTIP | Regulates integrin-mediated adhesion; degraded by HCMV to modulate DC migration | Viral immune evasion |
| CXCR4 | Chemokine receptor involved in DC migration; potential target of negative regulation | Inferred from chemotaxis pathways |
| CCR5 | Chemokine receptor involved in DC migration; potential target of negative regulation | Inferred from chemotaxis pathways |
| P2RX7 | Purinergic receptor that can modulate DC migration | Inflammation and immune regulation |
| PANX1 | Pannexin channel involved in cell migration regulation | Immune cell migration |
| ITGAM | Integrin subunit alpha M; involved in DC adhesion and migration | Adhesion regulation |
| ITGB2 | Integrin subunit beta 2; involved in DC adhesion and migration | Adhesion regulation |
| RAC1 | Rho GTPase regulating actin cytoskeleton during migration | Cell motility |
| CDC42 | Rho GTPase regulating actin cytoskeleton during migration | Cell motility |
| RHOA | Rho GTPase regulating actomyosin contraction during migration | Cell motility |
How Is negative regulation of dendritic cell chemotaxis Regulated?
The negative regulation of dendritic cell chemotaxis is itself controlled at multiple levels. Cytokines such as IFN-gamma and IFN-beta act as upstream inducers, triggering signaling cascades that involve STAT-1 activation. Nuclear receptors like LXRs respond to metabolic ligands and transcriptionally regulate chemotaxis. Viral proteins can hijack this regulation by targeting adhesion molecules like CYTIP. Additionally, purinergic signaling through receptors such as P2RX7 and pannexin channels can modulate DC migration. These layers of regulation ensure that DC trafficking is finely tuned to the immunological context.
negative regulation of dendritic cell chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IFNG | Autoimmunity, chronic inflammation | Ifng knockout mice; DC migration assays |
| IFNB1 | Multiple sclerosis, viral infections | Ifnb1 knockout mice; EAE model |
| STAT1 | Immunodeficiency, autoimmunity | Stat1 knockout mice; DC migration assays |
| NR1H2/NR1H3 | Atherosclerosis, metabolic syndrome | LXR double knockout mice; DC migration assays |
| CYTIP | HCMV infection, immune evasion | CYTIP knockdown in human DCs; HCMV infection |
Autoimmunity and Chronic Inflammation
Impaired negative regulation of dendritic cell chemotaxis can lead to excessive DC migration to lymph nodes and tissues, promoting autoimmunity and chronic inflammation. For example, IFN-gamma, a key negative regulator, is critical for limiting DC migration and preventing overactivation of T cells. In asthma, purinergic regulation of airway inflammation involves DC migration, and dysregulation may contribute to disease pathogenesis. Targeting pathways that enhance negative regulation could be therapeutic in autoimmune conditions.
Viral Infections and Immune Evasion
Human cytomegalovirus (HCMV) induces degradation of CYTIP to modulate dendritic cell adhesion and migration, likely as an immune evasion strategy. By altering DC trafficking, HCMV may impair T cell priming and establish latency. Understanding how viruses manipulate negative regulation of DC chemotaxis can inform antiviral strategies and vaccine design.
Cancer Immunotherapy
Tumor-derived factors can suppress dendritic cell migration, limiting anti-tumor T cell responses. IFN-beta, which negatively regulates DC migration, has complex roles in cancer; while it can inhibit DC migration, it also enhances antigen presentation. Modulating negative regulators of DC chemotaxis may improve the efficacy of cancer immunotherapies by promoting DC migration to tumors and lymph nodes.
From negative regulation of dendritic cell chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IFN-gamma negatively regulate DC chemotaxis in vivo? | Ifng knockout mice with DC migration assays |
| What is the role of STAT1 in IFN-beta-mediated suppression of DC migration? | Stat1 knockout mice or STAT1 knockdown in DCs |
| How do LXRs transcriptionally regulate DC chemotaxis? | LXR alpha/beta double knockout mice; ChIP-seq |
| Does CYTIP degradation by HCMV affect DC migration? | CYTIP knockout human DCs; HCMV infection |
| Can overexpression of CCR7 overcome negative regulation? | CCR7 knock-in or overexpression in DCs |
| What is the effect of point mutations in CCR7 on DC migration? | CRISPR knock-in of CCR7 mutants in DC lines |
How to Study the negative regulation of dendritic cell chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transwell migration assay | Number of cells migrating toward chemokine | Testing IFN-gamma effect on DC migration |
| Live cell imaging | Speed, directionality, and persistence of migration | Visualizing DC trafficking in lymph nodes |
| RNA-seq | Global gene expression changes | Identifying CCR7 and MMP9 suppression by IFN-beta |
| ChIP-seq | Transcription factor binding sites | Mapping LXR binding in DCs |
| CRISPR knockout screen | Genes affecting chemotaxis | Discovering novel negative regulators |
| Western blot | Protein expression levels | Validating STAT1 activation and CYTIP degradation |
| Flow cytometry | Cell surface receptor expression | Measuring CCR7 downregulation |
| Intravital microscopy | Real-time DC migration in vivo | Studying DC trafficking in infection models |
Transwell Migration Assays
Transwell assays are widely used to measure dendritic cell chemotaxis in vitro. DCs are placed in the upper chamber and chemokines such as CCL19 or CCL21 in the lower chamber; migration is quantified by counting cells that traverse the membrane. This method can be adapted to test negative regulators by treating DCs with IFN-gamma or IFN-beta and assessing reduced migration.
Live Cell Imaging
Live imaging of DCs in 3D matrices or in vivo allows real-time visualization of migratory behavior. Fluorescently labeled DCs can be tracked in lymph nodes or skin explants to study how negative regulators alter speed, directionality, and persistence. This technique provides spatial and temporal insights that endpoint assays cannot.
Transcriptomics and RNA-seq
RNA sequencing of DCs treated with negative regulators (e.g., IFN-beta) can reveal changes in gene expression, such as downregulation of CCR7 and MMP9. Comparative transcriptomics between wild-type and knockout DCs helps identify pathways controlled by specific regulators like LXRs.
CRISPR Screens
Genome-wide CRISPR knockout screens can identify genes whose loss enhances or suppresses DC chemotaxis. By coupling chemotaxis assays with sgRNA libraries, researchers can discover novel negative regulators. This unbiased approach is powerful for mapping the regulatory landscape of DC migration.
How CRISPR Can Be Used to Study GO:2000509 negative regulation of dendritic cell chemotaxis
Knockout
CRISPR knockout of candidate negative regulators (e.g., Stat1, Ifngr1) in dendritic cells can abolish the suppression of chemotaxis, leading to enhanced migration. This approach helps establish causality and identify essential genes. For example, Stat1 knockout DCs are resistant to IFN-beta-mediated inhibition of migration.
Point Mutation
Introducing point mutations in chemokine receptors like CCR7 or signaling molecules like STAT1 can dissect specific phosphorylation sites or binding interfaces required for negative regulation. CRISPR knock-in of phospho-deficient mutants allows precise functional analysis.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) into endogenous loci such as Ccr7 or Mmp9 enables real-time tracking of protein expression and localization during DC migration. This can reveal how negative regulators alter protein dynamics.
Overexpression
Overexpression of negative regulators (e.g., IFN-beta, LXR) or their downstream effectors using CRISPR activation or lentiviral delivery can suppress DC chemotaxis. This approach is useful for testing therapeutic potential and identifying downstream targets.
How EDITGENE Supports negative regulation of dendritic cell chemotaxis Research
Researchers studying negative regulation of dendritic cell chemotaxis-related genes often need to determine whether a candidate gene is causally involved in suppressing DC migration. EDITGENE provides comprehensive CRISPR-based services to facilitate this research, from knockout to overexpression models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of dendritic cell chemotaxis research.
Frequently Asked Questions About negative regulation of dendritic cell chemotaxis
What is negative regulation of dendritic cell chemotaxis?
It is any process that stops, prevents, or reduces the frequency, rate, or extent of dendritic cell chemotaxis, as defined by GO:2000509.
What genes are involved in negative regulation of dendritic cell chemotaxis?
Key genes include IFNG, IFNB1, STAT1, CCR7, MMP9, NR1H2, NR1H3, and CYTIP.
How does IFN-gamma negatively regulate dendritic cell chemotaxis?
IFN-gamma negatively regulates DC migration and T cell priming, acting as a brake on DC trafficking.
What is the role of STAT1 in dendritic cell chemotaxis?
STAT1 mediates IFN-beta-induced suppression of CCR7 and MMP9, thereby inhibiting DC migration.
How do liver X receptors regulate dendritic cell chemotaxis?
LXRs are transcriptional regulators of DC chemotaxis, linking lipid metabolism to immune cell trafficking.
Can viruses manipulate negative regulation of dendritic cell chemotaxis?
Yes, human cytomegalovirus induces degradation of CYTIP to modulate DC adhesion and migration.
What diseases are associated with dysregulated dendritic cell chemotaxis?
Autoimmunity, chronic inflammation, viral infections, and cancer.
What methods are used to study negative regulation of dendritic cell chemotaxis?
Transwell assays, live imaging, RNA-seq, ChIP-seq, and CRISPR screens.
How can CRISPR be used to study this process?
CRISPR knockout, knock-in, point mutation, and overexpression models can dissect gene function in DC migration.
Why is negative regulation of dendritic cell chemotaxis important for immunotherapy?
It influences DC migration to tumors and lymph nodes, affecting T cell priming and anti-tumor immunity.
Conclusion
GO:2000509, negative regulation of dendritic cell chemotaxis, is a critical biological process that ensures dendritic cells do not over-migrate, thereby maintaining immune homeostasis. Key regulators include cytokines like IFN-gamma and IFN-beta, transcription factors such as STAT1, nuclear receptors LXRs, and viral modulators like CYTIP. Dysregulation of this process contributes to autoimmunity, chronic inflammation, viral evasion, and cancer. Advances in CRISPR-based models and high-throughput methods are accelerating the discovery of new players in this pathway. EDITGENE provides essential tools to study these mechanisms, from knockout to overexpression, empowering researchers to translate findings into therapies.
References
- 2. Harcha PA et al.. 2021. Pannexin Channel Regulation of Cell Migration: Focus on Immune Cells.. Front Immunol 12:750480 PMID: 34975840
- 4. Koeppen M et al.. 2011. Purinergic regulation of airway inflammation.. Subcell Biochem 55:159-93 PMID: 21560048
- 5. Wu X et al.. 2006. Novel function of IFN-gamma: negative regulation of dendritic cell migration and T cell priming.. J Immunol 177(2):934-43 PMID: 16818748
- 6. Beceiro S et al.. 2018. Liver X Receptor Nuclear Receptors Are Transcriptional Regulators of Dendritic Cell Chemotaxis.. Mol Cell Biol 38(10) PMID: 29507185
- 7. Grosche L et al.. 2017. Human Cytomegalovirus-Induced Degradation of CYTIP Modulates Dendritic Cell Adhesion and Migration.. Front Immunol 8:461 PMID: 28484459
- 8. Yen JH et al.. 2010. IFN-beta inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9.. J Immunol 184(7):3478-86 PMID: 20190134
